Fig. 9
From: Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
Analysis of the predictive ability of risk signature for immunotherapy and chemotherapy. A–D Association between IPS, TIDE, TMB, neoantigens, and the risk signature. E MSI difference analysis based on mantis between high- and low-risk groups. F Association analysis between MSI status (based on PreMSIm) and risk score. G Distribution analysis of MSI status in high- and low-risk groups. H The boxplot represents immune checkpoint expression in the high- and low-risk groups. I The difference in chemosensitivity of 6 commonly used anticancer drugs in the high- and low-risk groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS. p > 0.05)